Changmao Biochemical Engineering Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Changmao Biochemical Engineering.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Chemicals earnings growth	44.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Aug 02

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Nov 18

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Apr 28

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Aug 03

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

May 04

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Feb 23

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

Jan 26

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

Dec 02

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Changmao Biochemical Engineering has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:954 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	637	-86	-142	-2	N/A
9/30/2023	640	-21	-170	-12	N/A
6/30/2023	644	45	-199	-22	N/A
3/31/2023	687	63	-202	-1	N/A
12/31/2022	730	81	-204	20	N/A
9/30/2022	707	90	-211	25	N/A
6/30/2022	684	99	-217	31	N/A
3/31/2022	616	79	-201	12	N/A
12/31/2021	548	58	-184	-7	N/A
9/30/2021	509	30	N/A	N/A	N/A
6/30/2021	471	2	-98	14	N/A
3/31/2021	457	9	-59	36	N/A
12/31/2020	444	17	-21	59	N/A
9/30/2020	430	24	N/A	N/A	N/A
6/30/2020	417	31	39	84	N/A
3/31/2020	456	45	58	101	N/A
12/31/2019	495	58	77	118	N/A
9/30/2019	557	69	64	97	N/A
6/30/2019	620	79	51	76	N/A
3/31/2019	629	65	31	60	N/A
12/31/2018	639	51	12	44	N/A
9/30/2018	633	34	24	60	N/A
6/30/2018	626	17	36	75	N/A
3/31/2018	629	10	26	70	N/A
12/31/2017	631	3	16	66	N/A
9/30/2017	625	8	N/A	61	N/A
6/30/2017	619	13	N/A	57	N/A
3/31/2017	607	23	N/A	53	N/A
12/31/2016	594	33	N/A	49	N/A
9/30/2016	569	42	N/A	47	N/A
6/30/2016	544	51	N/A	46	N/A
3/31/2016	530	48	N/A	59	N/A
12/31/2015	515	45	N/A	72	N/A
9/30/2015	519	40	N/A	82	N/A
6/30/2015	523	35	N/A	91	N/A
3/31/2015	543	36	N/A	94	N/A
12/31/2014	562	37	N/A	96	N/A
9/30/2014	606	48	N/A	91	N/A
6/30/2014	650	58	N/A	85	N/A
3/31/2014	677	66	N/A	N/A	N/A
12/31/2013	703	70	N/A	69	N/A
9/30/2013	699	60	N/A	N/A	N/A
6/30/2013	698	54	N/A	88	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 954's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if 954's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 954's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 954's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 954's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 954's Return on Equity is forecast to be high in 3 years time

Changmao Biochemical Engineering Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year Ended 31 December 2020

Recent updates

Chairman & Compliance Officer recently bought HK$836k worth of stock

Chairman & Compliance Officer recently bought HK$164k worth of stock

Changmao Biochemical Engineering Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.15 profit in FY 2022)

New minor risk - Financial data availability

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Chairman & Compliance Officer recently bought HK$59k worth of stock

Chairman & Compliance Officer recently bought HK$231k worth of stock

Chairman & Compliance Officer recently bought HK$54k worth of stock

Chairman & Compliance Officer recently bought HK$327k worth of stock

Chairman & Compliance Officer recently bought HK$277k worth of stock

New major risk - Financial position

First half 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.077 in 1H 2022)

Changmao Biochemical Engineering Company Limited to Report First Half, 2023 Results on Aug 18, 2023

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Changmao Biochemical Engineering Company Limited approves Final Dividend for the Year Ended 31 December 2022, Payable on 18 July 2023

Upcoming dividend of CN¥0.077 per share at 8.4% yield

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in FY 2021)

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.077 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited Announces Appointment of Ms. Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee, and Member of Remuneration Committee and Nomination Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited to Report First Half, 2022 Results on Aug 18, 2022

Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Changmao Biochemical Engineering Company Limited Appoints Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee and Member of Remuneration Committee and Nomination Committee

Changmao Biochemical Engineering Company Limited Approves Board Resignations, Effective 18 June 2022

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Less than half of directors are independent

Changmao Biochemical Engineering Company Limited Omits Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Upcoming dividend of CN¥0.02 per share

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

Full year 2020 earnings released: EPS CN¥0.032 (vs CN¥0.11 in FY 2019)

Full year 2020 earnings released

Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year Ended 31 December 2020

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

New 90-day high: HK$0.65

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

New 90-day low: HK$0.56

First half earnings released

New 90-day low - HK$0.59

First half earnings released

Changmao Biochemical Engineering Company Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day low - HK$0.60

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies